DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has made an investment in Novomer Inc. The companies also plan to sign
a cooperation agreement. Financial details of the investment will not be
disclosed.
Following the mid-term evaluation of DSM’s strategy Vision 2010 – Building on
Strengths, DSM will accelerate its transformation towards a leading Life
Sciences and Materials Sciences company. DSM Dyneema fits very well in this
strategy. For transparency reasons, it has therefore been decided to position
DSM Dyneema as a separate business group within the Performance Materials
cluster with effect from January 1, 2008.
Royal DSM N.V. has repurchased 522,792 of its own shares in the period from 6
December 2007 up to and including 12 December 2007 at an average price of EUR
34.52. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Today, DSM announces its official sponsoring of the Swiss Fencing team. In the
run-up to the Beijing Olympics, DSM is supporting the team lead by Marcel
Fisher, who won the Olympic gold medal in Athens in 2004.
Royal DSM N.V. has repurchased 608,500 of its own shares in the period from 29
November 2007 up to and including 5 December 2007 at an average price of EUR
34.18. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
DSM Anti-Infectives, a business group of Royal DSM N.V., the global life
sciences and materials sciences company headquartered in the Netherlands, and
Mumbai (IN) based Arch Pharmalabs Ltd., a pharmaceutical company manufacturing
active pharmaceutical ingredients (APIs), have signed a partnership agreement.
DSM, innovative ‘Partner in Sport’ of the Dutch Olympic Committee/Dutch Sports
Federation (NOC*NSF), is today presenting cooling products that the Dutch
Olympic athletes will be using during next year’s Summer Olympics.
Royal DSM N.V. has repurchased 709,000 of its own shares in the period from 22
November 2007 up to and including 28 November 2007 at an average price of EUR
32.74. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
DSM NeoResins+ has successfully completed the new water-based alkyd
manufacturing unit at its existing site located in Hoek van Holland (the
Netherlands).
Royal DSM N.V. has repurchased 876,612 of its own shares in the period from 15
November 2007 up to and including 21 November 2007 at an average price of EUR
33.61. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Royal DSM N.V. has repurchased 933,109 of its own shares in the period from 8
November 2007 up to and including 14 November 2007 at an average price of EUR
36.11. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Royal DSM N.V. has repurchased 540,500 of its own shares in the period from 1
November 2007 up to and including 7 November 2007 at an average price of EUR
38.34. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has participated in a financing round in Ganeden Biotech, Inc., a US
probiotics company which markets dietary supplements focused on digestive
health.
Royal DSM N.V. has repurchased 518,121 of its own shares in the period from 25
October 2007 up to and including 31 October 2007 at an average price of EUR
38.66. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Royal DSM N.V. has repurchased 636,366 of its own shares in the period from 18
October 2007 up to and including 24 October 2007 at an average price of EUR
38.82. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Organic growth of 5% in Q3 2007 due to higher volumes (3%) and prices (2%).
Operating profit from continuing operations above Q3 2006 level, despite
negative impact of currency exchange rates. Earnings per share
increased by 11%. New share buy-back program (EUR 750 million) in
progress. Outlook: full-year 2007 operating profit (before exceptional
items) confirmed to be EUR 820 million with a narrowed range of +/-2%.
Royal DSM N.V. has repurchased 374,500 of its own shares in the period from 11
October 2007 up to and including 17 October 2007 at an average price of EUR
39.58. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Royal DSM N.V. has issued a EUR 750 million 5.25% bond due 2017. The high
demand from investors exceeded the company’s optimistic expectation. The order
book had an exceptionally high quality and totalled over EUR 5 billion and was
closed early.
Royal DSM N.V. has repurchased 639,000 of its own shares in the period from 4
October 2007 up to and including 10 October 2007 at an average price of EUR
39.29. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Royal DSM N.V. today announces that it will invest to expand Dyneema® UD
(UniDirectional bullet resistant sheet) production by 25% in its Greenville,
North Carolina (USA) manufacturing facility.
Royal DSM N.V. has decided to invest in capacity expansion and modernization
of the caprolactam plant at the Chemelot Industrial Park in Geleen (NL). The
total investment costs amount to EUR 25 million.
Jo van den Hanenberg, at present Executive Vice President and Chief
Information Officer (CIO), will retire as of 1 January 2008. As of the same
date Aloys Kregting will succeed Jo van den Hanenberg as Chief Information
Officer at DSM.
Royal DSM N.V. has repurchased 496,500 of its own shares in the period from 1
October 2007 up to and including 3 October 2007 at an average price of EUR
39.10. This is in accordance with the first phase of the share buyback
program, announced on 1 October 2007.
Royal DSM N.V. announces that in accordance with the share buy-back program
published on 27 September 2007 the company will today, 1 October 2007, start
the first phase of this EUR 750 million program.
Royal DSM N.V. announces the following management appointments.
Dries Ausems (1950), at present Director Investor Relations, will be appointed
Spend Area Director Petchem and Energy with DSM Sourcing, as per 1 January
2008. As per the same date Hans Vossen (1963) at present Director Corporate
Strategy and Planning, will succeed Dries Ausems.
Royal DSM N.V. today announces the development of a new polymer which extends
the portfolio for high performance engineering thermoplastics. The polymer,
described as PA4T, has been developed by DSM Engineering Plastics, the
inventor and global market leader in high performance polyamides with Stanyl®
46.
Today, the newly composed Managing Board of Royal DSM N.V. presents the
conclusions from its early, mid-term evaluation of the Vision 2010 – Building
on Strengths strategy.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has participated in an equity investment round in the Danish company
Upfront Chromatography, the world's leading developer of customized industrial
protein chromatography processes.
Royal DSM N.V. has decided to build a new factory for waterborne emulsion
resins. This new plant will produce waterborne emulsions to be marketed by DSM
NeoResins+. Production will come on stream at the end of 2008. The total
investment costs amount to EUR 30 million.
Today the Dutch government announced that it will provide funding of EUR 45
million to the BioMedical Materials program (BMM) which has been initiated by
DSM and the University of Maastricht.
Royal DSM N.V. today announces the start of an initiative to enter the market
of ultra high molecular weight polyethylene (UHMWPE) for use in total joint
arthroplasty and other medical devices.
Royal DSM N.V. today announces its newest innovation in carotenoids:
CAROPHYLL® Stay-Pink. This concept, adapted from nature, makes a generational
step in existing carotenoid technologies.
Royal DSM N.V. has repurchased 311,250 of its own shares in the period from 6
September 2007 up to and including 10 September 2007 at an average price of
EUR 37.10. This is in accordance with the second phase of the share buyback
program, announced on 27 April 2007.
Today Royal DSM N.V. announces that it will restructure the manufacturing
activities of DSM Nutritional Products in China and develop the Xinghuo site,
Shanghai as a strategic manufacturing base for DSM. As a result of this
restructuring, the Gonglu site, also located in Shanghai, will be closed.
Jan Paul de Vries (1958), at present Chief Marketing Officer and Corporate
Vice President Communications will be appointed Business Group Director DSM
Elastomers as of January 1, 2008. As of November 1, 2007, Angelique
Paulussen-Hoogakker (1959) will therefore be appointed as Senior Vice
President Corporate Communications (reporting directly to the Managing Board).
Royal DSM N.V. has repurchased 519,921 of its own shares in the period from 30
August 2007 up to and including 5 September 2007 at an average price of EUR
37.37. This is in accordance with the second phase of the share buyback
program, announced on 27 April 2007.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has made an equity investment of EUR 2 million in Jurilab Oy, a
Finnish company specialized in the discovery of gene-disease associations and
their application to healthcare.
Royal DSM N.V. today announces that the construction of the DSM China Campus
in the Zhangjiang Hi-Tech Park in the Pudong New Area of Shanghai (PRC) has
commenced.
Royal DSM N.V. has repurchased 518,451 of its own shares in the period from 23
August 2007 up to and including 29 August 2007 at an average price of EUR
37.09. This is in accordance with the second phase of the share buyback
program, announced on 27 April 2007.
Dr R. John Wallace, of the Rowett Research Institute in Aberdeen, Scotland
(UK), has been awarded the DSM Nutrition Award 2007 in recognition of his
pioneering research in the field of animal nutrition.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has made an investment in Food Quality Sensor International Inc.
(FQSI).
Royal DSM N.V. has repurchased 1,084,729 of its own shares in the period from
16 August 2007 up to and including 22 August 2007 at an average price of EUR
35.89. This is in accordance with the second phase of the share buyback program
, announced on 27 April 2007. The consideration of this repurchase was EUR
38.9 million.
Royal DSM N.V. has repurchased 870,659 of its own shares in the period from 9
August 2007 up to and including 15 August 2007 at an average price of EUR
36.34. This is in accordance with the second phase of the share buyback
program, announced on 27 April 2007.
Royal DSM N.V. announces the following management appointments which will take
effect on 1 January 2008. The handover of responsibilities will take place in
the fourth quarter of 2007.
Royal DSM N.V. has repurchased 658,767 of its own shares in the period from 2
August 2007 up to and including 8 August 2007 at an average price of EUR
37.73. This is in accordance with the second phase of the share buyback
program, announced on 27 April 2007.
Royal DSM N.V. has repurchased 1,140,852 of its own shares in the period from
26 July 2007 up to and including 1 August 2007 at an average price of EUR
37.74. This is in accordance with the second phase of the share buyback
program , announced on 27 April 2007.
Today, one year before the Olympics in China, DSM and the Dutch Olympic
Committee/Dutch Sports Federation (NOC*NSF) are presenting two innovations in
the field of sports nutrition. PeptoPro® powder and a special grade of Lafti®
for sportspeople will be made available to the Dutch Olympic team in the
run-up to and during the Olympics.
Royal DSM N.V. has repurchased 598,725 of its own shares in the period from 19
July 2007 up to and including 25 July 2007 at an average price of EUR 37.23.
This is in accordance with the second phase of the share buyback program,
announced on 27 April 2007.
Organic growth of 5% in Q2 2007 due to higher volumes (2%) and prices (3%).
Operating profit from continuing operations 3% lower than in Q2 2006,
substantially impacted by currency exchange rates. Earnings per share before
exceptional items increased by 8%. Conclusions of Vision 2010 mid-term
evaluation to be presented at the September Analysts’ Conference. Outlook:
full-year 2007 operating profit now expected to be EUR 790 million +/-3%
(versus EUR 760 million +/- 5% indicated in Q1 report).
Royal DSM N.V. has repurchased 521,335 of its own shares in the period from 12
July 2007 up to and including 18 July 2007 at an average price of EUR 37.60.
This is in accordance with the second phase of the share buyback program,
announced on 27 April 2007.
Royal DSM N.V. has repurchased 474,294 of its own shares in the period from 5
July 2007 up to and including 11 July 2007 at an average price of EUR 37.32.
This is in accordance with the second phase of the share buyback program,
announced on 27 April 2007.
Following the installation of a Corporate Scientific Advisory Board in June
2007, DSM has now decided to establish a Biomedical Scientific Advisory Board
to support the company in its ambitions to become a world leader in biomedical
materials.
Royal DSM N.V. has repurchased 569,782 of its own shares in the period from 28
June 2007 up to and including 4 July 2007 at an average price of EUR 36.66.
This is in accordance with the second phase of the share buyback program,
announced on 27 April 2007.
Royal DSM N.V. today announces that privately owned Pentapharm Holding Ltd.
and DSM Nutritional Products Ltd. have signed an agreement on the sale and
purchase of 100% of the Pentapharm’s shares to DSM.
On 29 June 2007 Mr. Wen Jia Bao, Premier of the State Council of the Peoples
Republic of China visited DSM Citric Acid (Wuxi) Limited in recognition of its
outstanding safety, health and environmental (SHE) performance.
Royal DSM N.V. has repurchased 607,831 of its own shares in the period from 21
June 2007 up to and including 27 June 2007 at an average price of EUR 36.48.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Royal DSM N.V. has repurchased 1,130,184 of its own shares in the period from
14 June 2007 up to and including 20 June 2007 at an average price of EUR
37.24. This is in accordance with the second phase of the share buyback
program announced on 27 April 2007.
Royal DSM N.V. has repurchased 733,353 of its own shares in the period from 7
June 2007 up to and including 13 June 2007 at an average price of EUR 37.14.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Royal DSM N.V. has repurchased 805,650 of its own shares in the period from 31
May 2007 up to and including 6 June 2007 at an average price of EUR 37.49.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Royal DSM N.V. today announces that AstraZeneca (LSE: AZN, NYSE: AZN) has
acquired the biologics manufacturing facility in Montreal, Canada, from DSM
Biologics Inc. This transaction will lead to a small book profit for DSM.
Royal DSM N.V. has repurchased 462,184 of its own shares in the period from 24
May 2007 up to and including 30 May 2007 at an average price of EUR 36.71.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Royal DSM N.V. has repurchased 1,073,003 of its own shares in the period from
17 May 2007 up to and including 23 May 2007 at an average price of EUR 36.52.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Royal DSM N.V. has repurchased 714,591 of its own shares in the period from 10
May 2007 up to and including 16 May 2007 at an average price of EUR 34.92.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Royal DSM N.V. has repurchased 527,467 of its own shares in the period from 3
May 2007 up to and including 9 May 2007 at an average price of EUR 34.90. This
is in accordance with the second phase of the share buyback program announced
on 27 April 2007.
Royal DSM N.V. has repurchased 504,980 of its own shares in the period from 27
April 2007 up to and including 2 May 2007 at an average price of EUR 34.77.
This is in accordance with the second phase of the share buyback program
announced on 27 April 2007.
Sales up 4% from Q1 2006. Operating profit from continuing operations 7% lower
than in Q1 2006, significantly impacted by currency exchange rates. Share
buy-back program resumed as of today (remaining amount EUR 508 million).
Outlook: 2007 operating profit expected to be EUR 760 million +/- 5%.
Royal DSM N.V. announces that in accordance with the share buy-back program
announced on 27 September 2006 the company will today, 27 April 2007, start
the second phase of this EUR 750 million program.
The DSM Annual General Meeting of Shareholders on 28 March 2007 passed a
resolution to declare a dividend for 2006 of EUR 1.00 per ordinary share of
EUR 1.50 par value. An interim dividend of EUR 0.33 per ordinary share having
been paid on 11 August 2006, the final dividend for 2006 will amount to EUR
0.67 per ordinary share.
At the Annual General Meeting of Shareholders (AGM) held this afternoon, DSM
announced that the company is withdrawing its proposal to introduce a loyalty
dividend program.
Royal DSM N.V. (DSM), the world’s leading supplier of nutritional and pharma
ingredients, performance materials and industrial chemicals, today announces
that it will invest in a new plant for producing engineering plastics
compounds in India, in the Ranjangaon MIDC industrial zone about 60 km from
Pune.
Wei-Ming Jiang, currently Senior Vice President Strategic Projects Asia at
DSM’s Corporate Planning Department, has been appointed President DSM China as
of May 1, 2007.
There is a need for European standards on CO2 emissions per product, emission
rights should no longer be allocated per company but per product and a
European Agency is needed to prevent the overall emissions ceiling from being
exceeded.
Royal DSM N.V. (DSM) today received a copy of Franklin Mutual’s request to the
Enterprise Section of the Amsterdam Court of Appeals, in which the Court is
being asked to start a judicial inquiry. The request was made in connection
with DSM’s proposal to introduce a loyalty dividend program.
Royal DSM N.V. (DSM) announces that more than 4,500 shareholders opted to have
their shares pre-registered in January and February in the framework of the
loyalty dividend program as proposed by DSM.
SIGHT AND LIFE, the humanitarian initiative of DSM – the leading manufacturer
for nutritional ingredients – presented the book Nutritional Anemia at
BioVision 2007. The book aims to help fight the devastating health burden of
nutritional anemia throughout the world.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has made an equity investment in Harland Medical Systems, Inc., an
emerging US company that is marketing technologies and solutions in medical
coating applications.
Operating profit for 2006 EUR 835 million, 6% higher than in 2005. Net profit
EUR 547 million, up 4% from 2005. Solid volume growth (5%), especially in
Performance Materials (9%). Proposed dividend EUR 1.00 per ordinary share.
Outlook: Operating profit in 2007 expected to be lower than in 2006, but on
track with Vision 2010.
Royal DSM N.V. and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX), today announce fermentation yields of more than 10 grams per liter for
monoclonal antibodies, a major breakthrough in the development of their PER.C6
technology platform.
Royal DSM N.V. today announces that it has decided to build a DSM China Campus
in the Zhangjiang Hi-Tech Park in the Pudong New Area of Shanghai (PRC). The
China Campus will comprise both all Shanghai offices of the DSM (China) Ltd.
Holding and several business groups and the R&D labs of DSM in China.
DSM is publishing a paper in the February 2007 issue of the renowned
scientific journal “Nature Biotechnology” announcing the release of the DNA
sequence of the fungus Aspergillus niger. The article – which has 69
co-authors – is the result of a research project carried out by DSM in which
twenty-nine international research groups participated.
